ESR1 and breast cancer: Similar studies in breast cancer have demonstrated that MASTL expression correlates significantly with increased CIN, mitotic index, histological grade, poor overall survival and with a high risk of metastatic relapse in estrogen receptor (ER) positive patients.25, 49, 52, 59